Conference Overview

 The Global Pharma AI Summit is a senior-level gathering for the scientists and R&D leaders applying AI across the drug lifecycle from early discovery through clinical development to regulatory submission. AI’s role in pharmaceutical R&D has moved past the proof-of-concept stage and the first wave of AI-originated candidates are now reaching Phase III, the point where the science either holds up under real evidentiary scrutiny or forces a recalibration of what AI can actually deliver. 

At the same time, regulators are moving fast. The FDA and EMA issued their first-ever joint AI guidance in January 2026, the EU AI Act’s high-risk compliance deadline lands in August 2027, and FDA’s own AI credibility framework is expected to finalize around the same window. Scientists and R&D leaders are being asked to deliver AI-driven results and prove those results are regulator-ready, often with guidance still catching up to the pace of the science. 

This summit brings together 80–100 senior professionals from pharmaceutical and biotech R&D, regulatory science to work through these questions together, built entirely from primary research with the community, not a committee’s best guess. 

● Test AI Against Phase III Reality: Get a rigorous, non-promotional look at how AI-originated candidates are actually performing as they reach clinical validation 

● Close the Synthesizability Gap: Explore what separates a computationally generated molecule from one a chemist can actually build and manufacture 

● Go Beyond Blockbuster Pipelines: See how AI is being applied to harder, lower-data problems like rare disease, vaccine design, drug repurposing and not just the best-funded programs 

● Build Regulator-Ready Evidence: Understand what AI-generated clinical and discovery evidence actually needs to look like to satisfy FDA, EMA, and MHRA scrutiny 

● Navigate a Moving Regulatory Landscape: Get ahead of the EU AI Act’s 2027 deadline, the new FDA-EMA joint guiding principles, and FDA’s evolving credibility framework 

● Hear Directly from Regulators and Scientists: Engage in candid, closed-door dialogue with regulatory scientists and R&D leaders from across the pipeline.